Xtent looks to raise $75m at IPO (initial public offering)
This article was originally published in Clinica
Executive Summary
Menlo Park, California-based drug-eluting stent developer Xtent last week priced its initial public offering of 4.7 million shares at $16 per share.The stock will be listed on the Nasdaq under the symbol "XTNT". A further 705,000 shares have been optioned to the underwriters to cover over-allotments, if any.